A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

ClinicalTrials.gov ID: NCT02588625

Public ClinicalTrials.gov record NCT02588625. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a two part study. The purpose of Part A is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of BMS-986020. The purpose of Part B is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using two different doses of BMS-986020.

Study identification

NCT ID: NCT02588625
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Scleroderma

Interventions

BMS-986020 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2016 (Type not available)
Primary completion: Oct 2019 (Estimated)
Completion: Oct 2019 (Estimated)
Last update posted: Jul 22, 2016

2016 – 2019

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
Local Institution	Scottsdale	Arizona	85259	—
Local Institution	Los Angeles	California	90095	—
Local Institution	Stanford	California	94305	—
Local Institution	Aurora	Colorado	80045	—
Local Institution	Washington D.C.	District of Columbia	20037	—
Local Institution	Washington D.C.	District of Columbia	20057	—
Local Institution	Chicago	Illinois	60611	—
Local Institution	Baltimore	Maryland	21205	—
Local Institution	Boston	Massachusetts	02114	—
Local Institution	Boston	Massachusetts	02118	—
Local Institution	Ann Arbor	Michigan	48109	—
Local Institution	New Brunswick	New Jersey	08903	—
Local Institution	Albany	New York	12206	—
Local Institution	New York	New York	10021	—
Local Institution	New York	New York	10032	—
Local Institution	Cleveland	Ohio	44195	—
Local Institution	Pittsburgh	Pennsylvania	15219	—
Local Institution	Charleston	South Carolina	29425	—
Local Institution	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02588625, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 22, 2016 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02588625 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →